Genetic analysis of cytomegalovirus in malignant gliomas

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6815-6824

  Bhattacharjee, Bornali ^a   Renzette, Nicholas ^a   Kowalik, Timothy F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; VIRUS DNA;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER GRADING; CHILD; CONTROLLED STUDY; COPY NUMBER VARIATION; EMBRYO; FEMALE; GENE SEGREGATION; GENE SEQUENCE; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MALE; MOLECULAR PHYLOGENY; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; UL83 GENE; VIRAL GENETICS; VIRUS GENE; VIRUS REPLICATION;

ADULT; AGED; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENE DOSAGE; GLIOMA; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; VIRAL PROTEINS; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 84863991629     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00015-12     Document Type: Article

References (63)

1. Arnoult D, et al. 2004. Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc. Natl. Acad. Sci. U. S. A. 101:7988 -7993.
2. Asito AS, et al. 2010. Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect. Agents Cancer 5:13.
3. Bandelt H-J, Forster P, Röhl A. 1999. Median-joining networks for inferring intraspecific phylogenies. Mol. Biol. Evol. 16:37- 48.
4. Boccardo E, Villa LL. 2007. Viral origins of human cancer. Curr. Med. Chem. 14:2526 -2539.
5. Cinatl J, Vogel JU, Kotchetkov R, Doerr WH. 2004. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol. Rev. 28:59 -77.
6. Cobbs CS, et al. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:3347-3350.
7. Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. 2008. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 68:724 -730.
8. Crough T, Khanna R. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22:76 -98.
9. Das D, Bhattacharjee B, Sen S, Mukhopadhyay I, Sengupta S. 2010. Association of viral load with HPV16 positive cervical cancer pathogenesis: causal relevance in isolates harboring intact viral E2 gene. Virology 402:197-202.
10. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. 1988. Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152-2165.
11. Dolan A, et al. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85:1301-1312.
12. Dunn W, et al. 2003. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 100:14223-14228.
13. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. 2003. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) epidemiology and pathogenesis. Microbiol. Mol. Biol. Rev. 67:175-212.
14. Dziurzynski K, et al. 2011. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-11-0414.
15. Fontaine J, et al. 2005. High-level of correlation of human papillomavirus-16 DNA viral load estimates generated by three real-time PCR assays applied on genital specimens. Cancer Epidemiol. Biomarkers Prev. 14: 2200-2207.
16. Gallot G, et al. 2001. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4 and CD8 cytomegalovirus phosphoprotein pp65 epitope determination. J. Immunol. 167:4196-4206.
17. Gibson L, et al. 2004. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8 T-cell responses in children with congenital or postnatal human cytomegalovirus infection. J. Immunol. 172:2256 -2264.
18. Gladson C, Prayson LRA, Liu WM. 2010. The pathobiology of glioma tumor. Annu. Rev. Pathol. Mech. Dis. 5:33-50.
19. Hassan J, Connell J. 2007. Translational mini-review series on infectious disease: congenital cytomegalovirus infection: 50 years on. Clin. Exp. Immunol. 149:205-210.
20. Hsieh P-P, et al. 2007. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am. J. Clin. Pathol. 128:579 -584.
21. Hsu CH, et al. 2004. HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J. 23:2269 -2280.
22. Hüebner C, Petermann I, Browning BL, Shelling AN, Ferguson LR. 2007. Tri-allelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol. Biomarkers Prev. 16:1185-1192.
23. Kern F, et al. 2002. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185:1709 -1716.
24. Khan N, Cobbold M, Keenan R, Moss PAH. 2002. Comparative analysis of CD8 T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J. Infect. Dis. 185:1025-1034.
25. Kondo E, et al. 2004. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 103:630-638.
26. Krishnan A, et al. 2008. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance inHLAtransgenic murine models. Immunol. Lett. 120:108 -116.
27. Kumar S, Subramanian S. 2002. Mutation rates in mammalian genomes. Proc. Natl. Acad. Sci. U. S. A. 99:803- 808.
28. Lau SK, et al. 2005. Lack of association of cytomegalovirus with human brain tumors. Mod. Pathol. 18:838-843.
29. Lehrer S, et al. 2011. No circulating cytomegalovirus in five patients with glioblastoma multiforme. Anticancer Res. 31:959 -960.
30. Li H, Ruan J, Durbin R. 2008. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 18:1851-1858.
31. Lucas K, Bao GL, Bruggeman R, Dunham K, Specht C. 2011. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J. Neurooncol. 103:231-238.
32. Luo MH, Rosenke K, Czornak K, Fortunato EA. 2007. Human cytomegalovirus disrupts both ataxia telangiectasia mutated protein (ATM)-and ATM-Rad3-related kinase-mediated DNA damage responses during lytic infection. J. Virol. 81:1934 -1950.
33. Martin D, Gutkind JS. 2008. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27(Suppl 2):S31-S42.
34. Maussang D, et al. 2006. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 103:13068 -13073.
35. Michaelis M, Doerr HW, Cinatl J, Jr. 2009. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11:1-9.
36. Mitchell DA, et al. 2007. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 10:10 -18.
37. Mocarski ES, Shenk T, Pass RF. 2007. Cytomegalovirus, p 2701-2772. In Knipe DM, et al. (ed), Fields virology. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
38. Murphy E, et al. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 100:14976- 14981.
39. Nei M, Li WH. 1979. Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc. Natl. Acad. Sci. U. S. A. 76: 5269-5273.
40. Nei M, Gojobori T. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426.
41. Poltermann BS, et al. 2006. Lack of association of herpesviruses with brain tumors. J. Neurovirol. 12:90 -99.
42. Prins RM, Cloughesy TF, Liau LM. 2008. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N. Engl. J. Med. 359:539 -541.
43. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. 2012. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J. Virol. 86:854-864.
44. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF. 2011. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog. 7:e1001344. doi:10.1371/ journal.ppat.1001344.
45. Sabatier J, et al. 2005. Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br. J. Cancer 92:747- 750.
46. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
47. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. 2008. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116:79-86.
48. Sinzger C, Digel M, Jahn G. 2008. Cytomegalovirus cell tropism. Curr. Top. Microbiol. Immunol. 325:63- 83.
49. Slezak SL, et al. 2007. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J. Translational Med. 5:17.
50. Slinger E, et al. 2010. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6 STAT3 axis. Sci. Signal. 3:1-10.
51. Soroceanu L. 2008. HCMV microinfections in inflammatory diseases and cancer. J. Clin. Virol. 41:218 -223.
52. Soroceanu L, Cobbs CS. 2010. Is HCMV a tumor promoter? Virus Res. 157:193-203.
53. Strååt K, et al. 2009. Activation of telomerase by human cytomegalovirus. J. Natl. Cancer Inst. 101:441- 443.
54. Tamura K, Nei M, Kumar S. 2004. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc. Natl. Acad. Sci. U. S. A. 101:11030 -11035.
55. Tamura K, et al. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. c18 doi:10.1093/molbev/msr121.
56. Terrasson J, et al. 2005. p73-dependent apoptosis through death receptor: impairment by human cytomegalovirus infection. Cancer Res. 65: 2787-2794.
57. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673- 4680.
58. Wei J, et al. 2010. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16:461- 473.
59. Wei J, et al. 2011. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6:e16195. doi:10.1371/journal.pone.0016195.
60. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507.
61. Wills MR, et al. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569 -7579.
62. Ylitalo N, et al. 2000. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355:2194 -2198.
63. Yu N, et al. 2003. Low nucleotide diversity in chimpanzees and bonobos. Genetics 164:1511-1518.